Core Viewpoint - The announcement details the election of the third board of directors for Aojing Medical Technology Co., Ltd., including the appointment of a staff representative director and the restructuring of the board and management team [1][5][6]. Board Election and Restructuring - Aojing Medical held its third extraordinary general meeting on November 26, 2025, where the election of the third board of directors was approved, consisting of 9 directors, including 1 staff representative director [1][6]. - Helen Han Cui was elected as the staff representative director during the first staff representative assembly on November 26, 2025 [1][2]. - The newly elected board includes 5 non-independent directors and 3 independent directors, with a term of three years [1][8]. Management Appointments - The first meeting of the third board of directors approved the election of Huang Wanlan as the chairman and appointed new senior management, including Qiu Zhiye as the general manager and Tian Guofeng and Song Tianxi as deputy general managers [7][10]. - Wang Ling was appointed as the financial officer and also serves as the board secretary [10][14]. Legal Compliance and Qualifications - All elected directors and appointed senior management meet the qualifications set forth by the Company Law and the company's articles of association, with no disqualifications reported [4][11][15]. - The company has canceled its supervisory board, transferring its responsibilities to the audit committee of the board [12][13]. Shareholder Meeting and Voting - The extraordinary general meeting was conducted in compliance with legal requirements, with no resolutions being rejected [16][23]. - The voting process included both on-site and online participation, ensuring transparency and adherence to regulations [16][18].

Core Points - The company announced the convening of its first employee representative assembly for 2025 on November 26, 2025 [1] - Helen Han Cui has been elected as the employee representative director for the company's third board of directors [1]

Core Viewpoint - Aojing Medical announced the appointment of Qiu Zhiye as the company's secretary of the board on November 26 [1] Group 1 - Aojing Medical made an official announcement regarding the new appointment [1]

奥精医疗科技股份有限公司 证券代码：688613 证券简称：奥精医疗 公告编号：2025-063 关于选举第三届董事会职工代表董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 奥精医疗科技股份有限公司（以下简称"公司"）于2025年11月10日召开第二 届董事会第十七次会议，并于2025年11月26日召开2025年第三次临时股东大会， 审议通过了《关于取消监事会、增加注册资本并修订〈公司章程〉的议案》。 根据修订后的《奥精医疗科技股份有限公司章程》（以下简称"《公司章程》"）， 公司第三届董事会由9名董事组成，其中1名职工代表董事，由公司职工通过职 工代表大会选举产生。 公司于2025年11月26日召开2025年第一次职工代表大会，选举Helen Han Cui（崔菡）为公司第三届董事会职工代表董事（简历详见附件），将与公司股 东大会选举产生的5名非独立董事、3名独立董事共同组成公司第三届董事会， 任期三年，自本次职工代表大会审议通过之日起至第三届董事会届满之日止。 上述职工代表董事符合《公司法》等相关法律法规和 ...

证券代码： 688613 证券简称：奥精医疗 公告编号：2025-064 奥精医疗科技股份有限公司 关于完成董事会换届选举及聘任高级管理人员的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上海证券 交易所科创板股票上市规则》（以下简称"《科创板上市规则》"）、《上海证 券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、法规、 规范性文件及《奥精医疗科技股份有限公司章程》（以下简称"《公司章程》"） 等有关规定，奥精医疗科技股份有限公司（以下简称"公司"）于2025年11月26 日召开2025年第三次临时股东大会，选举产生了公司第三届董事会非独立董事 （不含职工代表董事）和独立董事，并与公司职工代表大会选举产生的职工代表 董事，共同组成公司第三届董事会。 公司于2025年11月26日召开第三届董事会第一次会议，审议通过了《关于 选举第三届董事会董事长的议案》《关于选举第三届董事会各专门委员会委员的 议案》《关于聘任公司总经理的议案》《关于聘任公 ...

2025年第三次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 证券代码：688613 证券简称：奥精医疗 公告编号：2025-062 奥精医疗科技股份有限公司 （二） 股东大会召开的地点：北京市大兴区庆丰西路 69 号 35 号楼 3 层 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 49 | | --- | --- | | 普通股股东人数 | 49 | | 2、出席会议的股东所持有的表决权数量 | 27,904,066 | | 普通股股东所持有表决权数量 | 27,904,066 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 20.3666 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 20.3666 | （四） 表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次会议由公司董事会召集，董事长 Eric Gang Hu 未出席，过半数董事按章程 选举董事黄晚兰主持。会议采用现场投票和网络投票相结 ...

法律意见书 北京市中伦律师事务所 关于奥精医疗科技股份有限公司 2025 年第三次临时股东大会的 法律意见书 致：奥精医疗科技股份有限公司 北京市中伦律师事务所（以下简称"本所"）接受奥精医疗科技股份有限公 司（以下简称"公司"）委托，指派律师见证公司 2025 年第三次临时股东大会 （以下简称"本次股东大会"）。本所律师根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司股东会规则》（以下简称"《股东会规则》"）、《律师事务所从事 证券法律业务管理办法》等相关法律、法规、规章、规范性文件及《奥精医疗科 技股份有限公司章程》（以下简称"《公司章程》"）的规定，对本次股东大会 的相关事项进行见证并出具法律意见。 为出具本法律意见书，本所律师审查了公司本次股东大会的有关文件和材料。 本所律师出具本法律意见书基于公司向本所律师提供的一切原始材料、副本、复 印件等材料、口头证言均是真实、准确、完整和有效的，不存在隐瞒记载、虚假 陈述或重大遗漏，有关文件的印章和签字均真实、有效，有关副本、复印件等材 料均与原始材料一致。 1 在本法律意见书中，本所律 ...

Core Insights - On November 21, Aojing Medical experienced a decline of 5.33% with a trading volume of 71.50 million yuan [1] - As of November 21, the total margin balance for Aojing Medical was 172 million yuan, representing 6.49% of its market capitalization [1] Financing Summary - On November 21, Aojing Medical had a financing buy-in amount of 6.40 million yuan and a financing repayment of 6.40 million yuan, resulting in a net financing buy of -4946 yuan [1] - The current financing balance of 172 million yuan is above the 90th percentile of the past year, indicating a high level of financing activity [1] Shareholder and Financial Performance - As of September 30, Aojing Medical had 9,862 shareholders, an increase of 15.44% from the previous period, while the average circulating shares per person decreased by 13.37% to 13,892 shares [2] - For the period from January to September 2025, Aojing Medical reported a revenue of 156 million yuan, a year-on-year increase of 5.22%, and a net profit attributable to shareholders of 13.94 million yuan, reflecting a significant year-on-year growth of 185.19% [2] Dividend and Institutional Holdings - Since its A-share listing, Aojing Medical has distributed a total of 58.67 million yuan in dividends, with 22.40 million yuan distributed over the past three years [3] - As of September 30, 2025, the eighth largest circulating shareholder is Rongtong Health Industry Flexible Allocation Mixed A/B, holding 2.40 million shares as a new shareholder [3]

Core Insights - The 24th Chinese Orthopaedic Association (COA) conference showcased significant advancements in orthopedic technology, emphasizing the integration of robotics, navigation, imaging, and biomaterials under the theme "Digital Intelligence in Orthopedics" [2] - The conference attracted 20,188 registered participants and received 37,222 submissions, indicating a strong interest in orthopedic innovations [2] Group 1: Robotics and Navigation Systems - Surgical robots and navigation systems are expanding across various orthopedic fields, moving beyond joint surgeries to include spine, trauma, and sports medicine, focusing on precision and standardization [4] - Companies like Stryker, Tianzhihang, and others are presenting comprehensive orthopedic platforms that integrate imaging, navigation, and robotic arms, forming a closed-loop system for enhanced surgical outcomes [4] - The Trinity system by Tuo Dao Medical demonstrates a unified platform for rapid switching between surgical procedures, showcasing advancements in AI planning and real-time navigation [19] Group 2: Biomaterials and Bone Repair - The competition in bone repair and biomaterials is intensifying, with companies offering innovative solutions such as absorbable screws and 3D-printed bioceramics, focusing on osteogenic activity and infection resistance [4] - Smartbone and other manufacturers are introducing advanced materials that not only fill defects but also promote bone regeneration and integration [4] Group 3: Domestic Innovations - Domestic companies are accelerating the development of high-end joint prosthetics and key materials, with a focus on integrating materials, prosthetic design, and manufacturing processes [4] - The collaboration between local firms and international companies is shifting from product showcases to establishing standards and ecosystems, enhancing the overall orthopedic landscape [4] Group 4: Key Product Launches - Stryker highlighted its latest products, including the Mako robotic system, which integrates multiple surgical techniques for hip and knee replacements, enhancing precision and efficiency [5][7] - Rosenboht signed a strategic partnership with the Chinese University of Hong Kong to advance intelligent surgical technologies, aiming for more precise and minimally invasive orthopedic procedures [12][14] - The launch of the "Panshi Self-Pressing 3D Partition Bone Trabecular Biological Knee Prosthesis" by Jiashite Medical showcases advancements in mechanical stability and biological fixation [40][42] Group 5: Technological Integration - Companies are increasingly focusing on integrating AI and imaging technologies to enhance surgical precision and safety, as seen in the solutions presented by Meiya Optical and other firms [46][50] - The introduction of AR navigation systems by Linyan Medical represents a significant technological advancement, improving the visibility and accuracy of spinal surgeries [53][55] Group 6: Comprehensive Solutions - The conference highlighted the importance of comprehensive solutions that encompass preoperative planning, intraoperative guidance, and postoperative evaluation, as demonstrated by various exhibitors [4][60] - Companies like Weigao and others are showcasing integrated solutions that leverage digital technologies to enhance the entire orthopedic treatment process [100][102]

证券代码：688613 证券简称：奥精医疗 奥精医疗科技股份有限公司 2025 年第三次临时股东大会 会议资料 二〇二五年十一月 | | | | 2025 | 年第三次临时股东大会会议须知 | 1 | | --- | --- | --- | | 2025 | 年第三次临时股东大会会议议程 | 3 | | 2025 | 年第三次临时股东大会会议议案 | 5 | 奥精医疗科技股份有限公司 2025 年第三次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 确保股东大会的正常秩序和议事效率，根据《公司法》《证券法》《上市公司股 东大会规则》《奥精医疗科技股份有限公司章程》《奥精医疗科技股份有限公司 股东大会议事规则》等有关规定，特制定本会议须知： 一、为保证本次大会的严肃性和正常秩序，除出席会议的股东、董事、监事、 高级管理人员、公司聘任律师及中介机构外，公司有权依法拒绝其他人员入场。 二、为确认出席大会的股东或其代理人或其他出席者的出席资格，会议工作 人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 三、请出席大会的股东或其代理人或其他出席者在会议召开前 ...